RT Journal Article
SR Electronic
T1 IDEAL—Lowering CHD Risk with High-Dose Statins
JF MD Conference Express
YR 2005
FD SAGE Publications
VO 5
IS 1
SP 27
OP 27
DO 10.1177/155989770501014
UL http://mdc.sagepub.com/content/5/1/27.abstract
AB The IDEAL (Incremental Decrease in Clinical Endpoints Through Aggressive Lipid Lowering) Trial compared high and low doses of statins over a five-year time period. The primary endpoint was a composite of heart attack, coronary heart disease death, or cardiac arrest with resuscitation. Secondary endpoints included the primary events plus unstable angina that required hospitalization, coronary artery bypass graft (CABG), or percutaneous coronary intervention (PCI).